

FOR IMMEDIATE RELEASE

Contact: Andrew Lavin

A. Lavin Communications

alc@alavin.com 516-944-4486

PathSensors, Inc. Receives a \$500,000 Investment for Market Expansion of its Rapid Pathogen Detection and Identification Systems

Private Investor Michael Song will also partner with PathSensors to Identify Food and Agricultural Pathogen test applications in China

BALTIMORE — PathSensors Inc., a bioscience and environmental testing company has received a \$500,000 investment from private investor Michael Song.

Song, who is president Shanghai Qi Fa Electronics Co. Ltd., in China is providing funding for market expansion of PathSensors pathogen detection systems in the U.S. He will also partner with PathSensors to expand market penetration in China of its surface and airborne detection systems, which deliver extremely rapid, highly reliable detection of bacteria, virus and toxins in minutes.

The PathSensor Zephyr detects foodborne pathogens such as salmonella, e.coli, listeria and campylobacter in dry foods, meats and on food preparation surfaces; significant issues for food producers worldwide. The Bioflash-AF is used for collection and identification of airborne pathogens in the agpoultry environment, using a single sample. Currently, PathSensors is engaged in programs with the USDA and FDA to identify pathogens in poultry and plant materials.

"PathSensors is the only technology platform available today that can quickly and efficiently detect air, surface and liquid based pathogens, within minutes in the field," Song says. "In China alone, I foresee tremendous opportunities in helping food processors cope with bird flu and salmonella with onsite sample testing in minutes. PathSensors will also have a rapid Ebola test early next year and can use the same technology for MERS and SARS detection as well, which is why I am so excited about this company."

"We're pleased to have Michael Song join our existing group of investors," says PathSensors President Ted Olsen. His expertise in the Chinese market will be helpful in expanding our easy-to-use detection systems."

PathSensors products leverage the CANARY® (Cellular Analysis and Notification

of Antigen Risks and Yields) technology which is licensed from the MIT-Lincoln Laboratory. With CANARY® biosensors, the rapid kinetics and signal amplification of cell-based signaling enables pathogen detection at sensitivities down to 50 cfu/pfu within 5 minutes.

About CANARY

CANARY® (Cellular Analysis and Notification of Antigen Risks and Yields) licensed from the MIT-Lincoln Laboratory delivers extremely rapid detection of more than 25 pathogens at previously unattainable levels of sensitivity and specificity. CANARY incorporates pathogen-specific antibodies expressed on the biosensor surface, which trigger bioluminescent proteins. The biosensor in the presence of a pathogen (virus, bacteria or toxin) binds surface bound antibodies triggering an intracellular calcium release, which activates the bioluminescent proteins and generates the emission of light.

PathSensors' financial partners include Blue Venture Investors, Empower Baltimore Management Corporation (EBMC), Chesapeake Emerging Opportunities Club and the Virginia Active Angel Network (VAAN).

About PathSensors, Inc.

PathSensors Inc., a biotech company headquartered in Baltimore, Maryland has developed and commercialized MIT-LL technology enabling the highly reliable identification of airborne and liquid-based pathogens. PathSensors currently offers the Zephyr and BioFlash systems to provide the rapid and highly reliable identification of airborne, liquid and surface-based pathogens. Government organizations and industry currently use these systems for monitoring, detection and identification of pathogens in biosecurity, mail screening, food processing, agriculture and environmental testing. PathSensors is privately held. For more information, please visit http://www.PathSensors.com, call 443.557.6150 or email info@PathSensors.com.